NASDAQ:MNKD MannKind Q2 2026 Earnings Report $4.08 -0.02 (-0.37%) As of 03:21 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast MannKind EPS ResultsActual EPSN/AConsensus EPS -$0.02Beat/MissN/AOne Year Ago EPSN/AMannKind Revenue ResultsActual RevenueN/AExpected Revenue$109.18 millionBeat/MissN/AYoY Revenue GrowthN/AMannKind Announcement DetailsQuarterQ2 2026Date8/5/2026TimeBefore Market OpensConference Call DateWednesday, August 5, 2026Conference Call Time9:00AM ETConference Call ResourcesEarnings HistoryCompany Profile MannKind Earnings HeadlinesMannKind Corporation (MNKD) Up 20% Since Afrezza FDA ApprovalJuly 10, 2026 | finance.yahoo.comMannKind (NASDAQ:MNKD) Upgraded by Wall Street Zen to "Hold" RatingJuly 5, 2026 | americanbankingnews.comThe only metrics you should watch as a day trader.Day traders and swing traders don't need the same metrics - and using the wrong ones costs you edge. After 40 years of trading experience, one chart detail stands out above all others as the primary signal before entering any trade. The Ultimate Day Trading Cheatsheet distills that edge into 7 pages, including 23 Golden Rules and a specific trade setup with a reported 94.2% win rate. It's available at no cost.July 16 at 1:00 AM | The TradingPub (Ad)MannKind (MNKD) Receives a Grant from Breakthrough T1DJuly 3, 2026 | insidermonkey.comIs MannKind Corporation (MNKD) A Good Stock To Buy Now?June 29, 2026 | finance.yahoo.comMannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1DJune 23, 2026 | globenewswire.comSee More MannKind Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like MannKind? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MannKind and other key companies, straight to your email. Email Address About MannKindMannKind (NASDAQ:MNKD) (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life. Learn more at mannkindcorp.com.View MannKind ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Revving Up Returns: Big Banks Race Through the Rate PlateauWhy Microsoft Is Playing a Different AI Game Than Big Tech—and Cash Flow Is the TestAI’s Power Crunch Fuels a Pivot for These 2 Oilfield StocksToast’s Comeback Story Is Getting Harder for Wall Street to IgnoreWhy Conagra’s Dividend Cut Could Be the Best Thing for InvestorsWhich Storage Stock Is Best Positioned to Win the AI Memory War?Cintas Keeps Beating Expectations—And the Story Isn’t Over Upcoming Earnings Fifth Third Bancorp (7/17/2026)Truist Financial (7/17/2026)Travelers Companies (7/17/2026)HDFC Bank (7/18/2026)ICICI Bank (7/18/2026)General Motors (7/21/2026)Northrop Grumman (7/21/2026)America Movil (7/21/2026)Alphabet (7/21/2026)Chubb (7/21/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
